[Articles] Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial

Attention!

On Life Science Network, we import abstract of articles published in the most popular journals. In addition, members of our network often upload full article pdfs of their research.

To access all content shared in our network and the source link, please sign up for an account. If you already have an account, sign in, or connect with LinkedIn, Google.